# Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

> **NCT00372073** · PHASE2 · TERMINATED · sponsor: **Cyclacel Pharmaceuticals, Inc.** · enrollment: 187 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** seliciclib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00372073
- **Lead sponsor:** Cyclacel Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08-09
- **Primary completion:** 2009-03-03
- **Final completion:** 2009-04-07
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2021-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00372073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00372073, "Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00372073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*